Long-term remission in a patient with erythroleukemia following interferon-alpha treatment.
A patient in second relapse of acute erythroleukemia (AEL) was treated with 10 MU of recombinant interferon (IFN)-alpha subcutaneously for 24 days after he had failed standard chemotherapy. Besides fever up to 38.9 degrees C and a transient raise in liver function parameters, treatment was well tolerated but had to be discontinued because of a severe decrease in white blood cell and platelet count. After termination of IFN treatment, both cell populations showed a continuous rise during the following weeks and hemoglobin increased concomitantly. Partial remission could be reached as was demonstrated by a decrease in PAS-positive erythroblasts in bone marrow biopsy. Further studies with IFN in patients with AEL refractory to cytostatic chemotherapy are recommended.
Department of Chemotherapy, University of Vienna, Austria.
G G
GG
Steger
C
C
Dittrich
A
A
Chott
K
K
Derfler
J D
JD
Schwarzmeier
D000328:Adult; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction
D007370:Interferon Type I; D011994:Recombinant Proteins